Senaparib — Investigational Agent
Other · Phase 3 · Impact Therapeutics
Mechanism of Action
A next-generation potent oral inhibitor of PARP1/2 that traps PARP on damaged DNA and blocks single-strand break repair, producing synthetic lethality in homologous-recombination-deficient (e.g., BRCA-mutated) tumors.
Investigational Indications
- Platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer
- HRD-positive gynecologic malignancies